Forensic Toxicology

, Volume 32, Issue 1, pp 105–115 | Cite as

Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products

  • Nahoko Uchiyama
  • Yoshihiko Shimokawa
  • Satoru Matsuda
  • Maiko Kawamura
  • Ruri Kikura-Hanajiri
  • Yukihiro Goda
Original Article


Two new types of synthetic cannabinoids, an AM-2201 benzimidazole analog (FUBIMINA, 1) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM, 2), and three newly emerged phenethylamine derivatives, 25B-NBOMe (3), 2C-N-NBOMe (4), and a 25H-NBOMe 3,4,5-trimethoxybenzyl analog (5), were detected in illegal products distributed in Japan. The identification was based on liquid chromatography–mass spectrometry (LC–MS) and gas chromatography–mass spectrometry (GC–MS), high-resolution MS, and nuclear magnetic resonance analyses. Different from the representative synthetic cannabinoids, such as JWH-018, which have a naphthoylindole moiety, compounds 1 and 2 were completely new types of synthetic cannabinoids; compound 1 had a benzimidazole group in place of an indole group, and compound 2 had a 4-methylpiperazine group in place of the naphthyl group. Compounds 3 and 4 were N-o-methoxybenzyl derivatives of 2,5-dimethoxyphenethylamines (25-NBOMe series), which had been previously detected in European countries, but have newly emerged in Japan. Compound 5 had an N-trimethoxybenzyl group in place of an N-o-methoxybenzyl group. Data on the chemistry and pharmacology of compounds 1, 2, and 5 have never been reported to our knowledge.


AM-2201 benzimidazole analog (FUBIMINA) (4-Methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM) 25H-NBOMe 3,4,5-trimethoxybenzyl analog 25B-NBOMe 2C-N-NBOMe Synthetic cannabinoid 



Part of this work was supported by a Health and Labor Sciences Research Grant from the Ministry of Health, Labour, and Welfare, Japan.

Conflict of interest

There are no financial or other relations that could lead to a conflict of interest.


  1. 1.
    UNODC (2013) Global SMART update 2013—vol 10, September 2013. Accessed Sept 2013
  2. 2.
    UNODC (2013) The challenge of new psychoactive substances. A report from the global SMART programme, March 2013. Accessed Sept 2013
  3. 3.
    EMCDDA (2013) EMCDDA/Europol, 2005/387/JHA, EMCDDA-Europol 2012 annual report on the implementation of council decision, Lisbon, May 2013. Accessed May 2013
  4. 4.
    Kikura-Hanajiri R, Uchiyama N, Kawamura M, Goda Y (2013) Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012. Forensic Toxicol 31:44–53CrossRefGoogle Scholar
  5. 5.
    Kikura-Hanajiri R, Uchiyama N, Kawamura M, Ogata J, Goda Y (2013) Prevalence of new designer drugs and their legal status in Japan. Yakugaku Zasshi 133:31–40 (in Japanese with English abstract)PubMedCrossRefGoogle Scholar
  6. 6.
    Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol 31:223–240CrossRefGoogle Scholar
  7. 7.
    Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y (2013) New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol 31:93–100CrossRefGoogle Scholar
  8. 8.
    Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) Identification of two new-type designer drugs, a piperazine derivative MT-45 (I-C6) and a synthetic peptide Noopept (GVS-111), with a synthetic cannabinoid A-834735, a cathinone derivative 4-methoxy-α-PVP and a phenethylamine derivative 4-methylbuphedrine from illegal products. Forensic Toxicol. doi: 10.1007/s11419-013-0194-5 Google Scholar
  9. 9.
    Kikura-Hanajiri R, Uchiyama N, Kawamura M, Goda Y (2013) Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Drug Test Anal. doi: 10.1002/dta.1584
  10. 10.
    Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 227:21–32PubMedCrossRefGoogle Scholar
  11. 11.
    Lopyrev VA, Larina LI, Vakul’skaya TI, Shibanova EF, Titova IA, Voronkov MG, Liepins E (1982) Investigation of benzimidazoles. III. Transmission of the substituent effects in 2-substituted 1-methylbenzimidazoles studied by carbon-13 nuclear magnetic resonance. Org Magn Reson 20:212–216CrossRefGoogle Scholar
  12. 12.
    Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2012) Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicol 30:114–125CrossRefGoogle Scholar
  13. 13.
    Moir EM, Yoshiizumi K, Cairns J, Cowley P, Ferguson M, Jeremiah F, Kiyoi T, Morphy R, Tierney J, Wishart G, York M, Baker J, Cottney JE, Houghton AK, McPhail P, Osprey A, Walker G, Adam JM (2010) Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists. Med Chem Commun 1:54–60CrossRefGoogle Scholar
  14. 14.
    Zuba D, Sekuła K, Buczek A (2012) Identification and characterization of 2,5-dimethoxy-4-nitro-β-phenethylamine (2C-N)—a new member of 2C-series of designer drug. Forensic Sci Int 222:298–305PubMedCrossRefGoogle Scholar
  15. 15.
    Zuba D, Sekuła K, Buczek A (2013) 25C-NBOMe—new potent hallucinogenic substance identified on the drug market. Forensic Sci Int 227:7–14PubMedCrossRefGoogle Scholar
  16. 16.
    Silva ME, Heim R, Strasser A, Elz S, Dove S (2011) Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor. J Comput Aided Mol Des 25:51–66PubMedCrossRefGoogle Scholar
  17. 17.
    Acuña-Castillo C, Villalobos C, Moya PR, Sáez P, Cassels BK, Huidobro-Toro JP (2002) Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br J Pharmacol 136:510–519PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Association of Forensic Toxicology and Springer Japan 2013

Authors and Affiliations

  • Nahoko Uchiyama
    • 1
  • Yoshihiko Shimokawa
    • 1
  • Satoru Matsuda
    • 1
  • Maiko Kawamura
    • 1
  • Ruri Kikura-Hanajiri
    • 1
  • Yukihiro Goda
    • 1
  1. 1.National Institute of Health SciencesTokyoJapan

Personalised recommendations